The Medical Letter on Drugs and Therapeutics
Issue 1517
Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection; Nusinersen (Spinraza) for Spinal Muscular Atrophy; Exablate Neuro for Essential Tremor; Obeticholic Acid (Ocaliva) for Primary Biliary Cholangitis; Triferic for Iron Replacement; Inhibitors and Inducers of CYP Enzymes and P-Glycoprotein (online only)
The full issue is available to subscribers Subscriber Login   
Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection

The FDA has approved the fully human monoclonal antibody bezlotoxumab (Zinplava – Merck) for use with antibacterial drug treatment to reduce recurrence of Clostridium difficile infection (CDI) in adults with CDI at high risk for recurrence. It is the first drug to be approved for this indication.

CDI — CDI is the most common infectious cause of healthcare-associated diarrhea in adults. The incidence and severity of CDI have increased in recent years with the emergence of an epidemic hypervirulent strain (NAP1/B1/027).1 The recurrence rate after an initial episode of CDI is typically 20-25%. Patients who develop one recurrent episode have up to a 35% chance of having another one, and patients with at least three CDI episodes have up to a 65% chance of additional recurrences.2

STANDARD TREATMENT — ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this issue:
Title: Issue 1517
Select version:
 Downloadable, electronic issue - $35
 Postal, hardcopy issue - $35